RecruitingRecruiting
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
NCT07751991 · Charm Therapeutics
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029 as Monotherapy in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) With NPM1 Mutations, KMT2A or NUP98 Rearrangements
About this study
CHM-029-01 is a Phase 1/2, first-in-human, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antileukemic activity of orally administered CHM-029 in adults with relapsed or refractory acute myeloid leukemia (AML) with an NPM1 mutation, KMT2A rearrangement, or NUP98 rearrangement.
Eligibility criteria
Inclusion Criteria:
* 18 years old and above
* Relapsed or refractory (R/R) acute myeloid leukemia (AML) and has had treatment with any available standard therapies
* Positive for NPM1 mutation, or KMT2A or NUP98 rearrangements
Exclusion Criteria:
* White blood cell (WBC) count higher than 25,000 u/L that cannot be maintained below threshold with hydroxyurea treatment
* Extramedullary only AML
* Has current complications related to hematopoietic stem cell transplant (HSCT)
* Other cancers that require treatment
* Active Hepatitis or HIV infection
* Moderate hepatic or renal impairment
* Acute promyelocytic leukemia
* Baseline prolongation of QT/QTc interval (≥ 470 ms) or additional risk factors for Torsades de Pointes (TdP)
* Congestive heart failure NYHA Class 3 or 4
* Central nervous system involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation
Study design
Enrollment target: 40 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-09-28
Estimated completion: 2029-03
Last updated: 2026-11-06
Interventions
Drug: CHM-029
Primary outcomes
- • Number of participants with dose limiting toxicities (DLTs) (Baseline through Day 28)
- • Number of participants with adverse events (AEs) (Baseline through study completion, an average of 3 years)
- • Number of participants with adverse events (AEs) by severity (Baseline through study completion, an average of 3 years)
Sponsor
Charm Therapeutics · industry
Contacts & investigators
ContactCharm Study Contact · contact · clinicaltrials@charmtx.com · 312-682-0586
All locations (8)
City of Hope Center Medical CenterRecruiting
Duarte, California, United States
Yale - New Haven Hospital / Cancer CenterRecruiting
New Haven, Connecticut, United States
START MidwestRecruiting
Grand Rapids, Michigan, United States
Memorial Sloan Kettering Cancer CenterRecruiting
New York, New York, United States
Vanderbilt University Medical CenterRecruiting
Nashville, Tennessee, United States
The Christie NHS Foundation TrustRecruiting
Manchester, United Kingdom
Oxford University Hospitals NHS Foundation TrustRecruiting
Oxford, United Kingdom
Cardiff & Vale University HospitalRecruiting
Wales, United Kingdom